| Target Price | $606.71 |
| Price | $534.28 |
| Potential | 13.56% |
| Number of Estimates | 32 |
| 32 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $606.71. This is 13.56% higher than the current stock price. The highest price target is $719.25 34.62% , the lowest is $444.40 16.82% . | |
| A rating was issued by 40 analysts: 27 Analysts recommend Intuitive Surgical to buy, 12 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 13.56% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
37 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $10.0b . This is 3.90% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $10.5b 9.01% , the lowest is $9.4b 1.83% .
This results in the following potential growth metrics:
| 2024 | $8.4b | 17.24% |
|---|---|---|
| 2025 | $10.0b | 19.57% |
| 2026 | $11.4b | 14.45% |
| 2027 | $13.1b | 15.01% |
| 2028 | $14.2b | 8.23% |
| 2029 | $16.7b | 17.32% |
| 2030 | $19.5b | 16.91% |
| 2031 | $20.4b | 4.30% |
| 2032 | $22.6b | 11.14% |
37 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $3.0b . This is 8.61% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $3.1b 13.82% , the lowest is $2.8b 1.68% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | $2.3b | 29.18% |
|---|---|---|
| 2025 | $3.0b | 28.46% |
| 2026 | $3.4b | 13.54% |
| 2027 | $3.9b | 16.43% |
| 2028 | $4.4b | 11.31% |
| 2029 | $5.2b | 17.94% |
| 2030 | $6.5b | 25.21% |
| 2024 | 27.81% | 10.18% |
|---|---|---|
| 2025 | 29.87% | 7.41% |
| 2026 | 29.64% | 0.77% |
| 2027 | 30.00% | 1.21% |
| 2028 | 30.85% | 2.83% |
| 2029 | 31.02% | 0.55% |
| 2030 | 33.22% | 7.09% |
37 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $8.32 . This is 9.62% higher than earnings per share in the financial year 2024. The highest EPS forecast is $8.72 14.89% , the lowest is $7.79 2.64% .
This results in the following potential growth metrics and future valuations:
| 2024 | $6.42 | 27.63% |
|---|---|---|
| 2025 | $8.32 | 29.60% |
| 2026 | $9.45 | 13.58% |
| 2027 | $11.00 | 16.40% |
| 2028 | $12.25 | 11.36% |
| 2029 | $14.44 | 17.88% |
| 2030 | $18.08 | 25.21% |
| 2031 | $18.07 | 0.06% |
| 2032 | $19.59 | 8.41% |
| Current | 70.39 | 14.91% |
|---|---|---|
| 2025 | 64.20 | 8.80% |
| 2026 | 56.54 | 11.93% |
| 2027 | 48.56 | 14.11% |
| 2028 | 43.63 | 10.15% |
| 2029 | 36.99 | 15.22% |
| 2030 | 29.54 | 20.14% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 18.12 and an P/S ratio of 18.96 .
This results in the following potential growth metrics and future valuations:
| Current | 18.83 | 16.64% |
|---|---|---|
| 2025 | 18.12 | 3.77% |
| 2026 | 15.83 | 12.62% |
| 2027 | 13.77 | 13.05% |
| 2028 | 12.72 | 7.60% |
| 2029 | 10.84 | 14.76% |
| 2030 | 9.27 | 14.47% |
| 2031 | 8.89 | 4.13% |
| 2032 | 8.00 | 10.02% |
| Current | 19.70 | 14.88% |
|---|---|---|
| 2025 | 18.96 | 3.75% |
| 2026 | 16.57 | 12.63% |
| 2027 | 14.41 | 13.05% |
| 2028 | 13.31 | 7.60% |
| 2029 | 11.35 | 14.76% |
| 2030 | 9.71 | 14.47% |
| 2031 | 9.30 | 4.13% |
| 2032 | 8.37 | 10.02% |
Intuitive Surgical...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Neutral
➜
Neutral
|
Unchanged | Oct 23 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 22 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Oct 22 2025 |
| Raymond James |
Outperform
➜
Outperform
|
Unchanged | Oct 22 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 22 2025 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Oct 22 2025 |
| BTIG |
Buy
➜
Buy
|
Unchanged | Oct 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Oct 23 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 22 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Oct 22 2025 |
|
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Oct 22 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 22 2025 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Oct 22 2025 |
|
Unchanged
BTIG:
Buy
➜
Buy
|
Oct 22 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


